Guideline in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
34 authors.
Marisol BetenskyDivision of Hematology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD.ORCID 0000-0001-6725-3035
Muayad AzzamEvidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0000-0002-2046-8343
Rachel BercovitzDivision of Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.ORCID 0000-0001-6653-5946
Rukhmi V BhatDivision of Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.ORCID 0000-0002-1700-4804
Tina BissDepartment of Haematology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.ORCID 0000-0001-9986-4973
Brian BranchfordDivision of Hematology, Department of Pediatrics, Medical College of Wisconsin, Wauwatosa, WI.ORCID 0000-0002-4076-270X
Leonardo R BrandãoDivision of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-7711-4530
Anthony K C ChanDivision Pediatric Hematology/Oncology, Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-1551-3995
E Vincent S FaustinoDepartment of Pediatrics, Section of Critical Care, Yale School of Medicine, New Haven, CT.ORCID 0000-0001-6155-2691
Qais HamarshaEvidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0000-0001-9711-4650
Julie JaffrayDivision of Hematology/Oncology, Department of Pediatrics, Rady Children's Hospital-San Diego, San Diego, CA.ORCID 0000-0002-1175-7266
Sophie JonesFaculty of Medicine, Dentistry and Health Sciences, Department of Nursing, Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-9272-6540
Hassan KawtharanyEvidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0009-0007-3725-8485
Bryce A KerlinDivision of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH.ORCID 0000-0002-1756-8271
Jana KhawandiEvidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0000-0001-7581-4787
Grace KriderDepartment of Nursing, Ascension St. Vincent Indianapolis, Indianapolis, IN.
Nicole KucineDivision of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-4865-4033
Riten KumarDepartment of Pediatrics, Dana Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8004-4190
Christoph MaleDepartment of Paediatrics, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4989-6421
Paul MonagleDepartment of Pediatrics, Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-3970-8984
Marie-Claude Pelland-MarcotteDepartment of Pediatrics, Centre Hospitalier Universitaire de Québec, Centre Mère-Enfant, Québec City, QC, Canada.ORCID 0000-0003-2364-7205
Leslie RaffiniDivision of Hematology, Department of Pediatrics, University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0001-8152-1040
Chittalsinh RauljiDivision of Hematology/Oncology, Department of Pediatrics, University of Nebraska Medical Center, Children's Hospital Nebraska, Omaha, NE.ORCID 0009-0008-7610-7214
Sarah E SartainSection of Hematology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.ORCID 0000-0003-2204-4568
Clifford M TakemotoDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-2832-6884
Cristina TarangoDivision of Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-0283-9972
C Heleen van OmmenDepartment of Pediatric Hematology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID 0000-0001-9036-039X
Maria C VelezDivision of Hematology/Oncology, Department of Pediatrics, Louisiana State University Health Sciences Center/Children's Hospital New Orleans, New Orleans, LA.ORCID 0009-0006-9426-4075
Sara K VeselyDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences, Hudson College of Public Health, Oklahoma City, OK.ORCID 0000-0003-3448-0156
John WiernikowskiDivision of Hematology/Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-5058-3596
Suzan WilliamsDivision of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-9321-4301
Hope P WilsonDivision of Hematology/Oncology, Department of Pediatrics, Children's of Alabama, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.ORCID 0000-0001-8904-3338
Gary WoodsDivision of Hematology/Oncology, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0002-0921-0974
Reem A MustafaDivision of Nephrology, Department of Internal Medicine, Evidence-based Practice and Impact Center, The University of Kansas Health System, Kansas City, KS.ORCID 0000-0002-2091-0875
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.
backgroundVenous thromboembolism (VTE) is a significant cause of morbidity in children, particularly among hospitalized patients and those with chronic medical conditions. There is a lack of consensus on anticoagulant prophylaxis strategies.
objectiveThese evidence-based guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention.
methodsASH formed a multidisciplinary guideline panel that included 1 patient representative. The University of Kansas Health System supported the guideline development process, including systematic evidence reviews up to April 2025. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess certainty in the evidence and make recommendations.
resultsThe panel agreed on 12 recommendations. For pediatric patients with solid cancer, who have experienced trauma, or who are critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device.
conclusionsHigh-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. · full record | OpenQuestion